Estradiol Valerate Therapy in Postmenopausal Women

Introduction to Estradiol Valerate Therapy

• The American College of Physicians recommends starting with a dose of 2 mg weekly for estradiol valerate intramuscular injections in postmenopausal women, based on evidence from clinical studies showing efficacy at this dose level while minimizing risks associated with higher doses, as seen in the ESPRIT trial which evaluated estradiol valerate at 2 mg/day in postmenopausal women and found it effective for various outcomes 1

Dosing and Administration

• The US Preventive Services Task Force found that estrogen therapy, such as estradiol valerate, is associated with increased risk of stroke, gallbladder disease, and urinary incontinence, highlighting the need for careful dosing and administration, with starting doses of 2 mg weekly allowing for gradual titration based on symptom response and minimizing risks of thromboembolism and cardiovascular events associated with higher estrogen levels 2

Contraindications and Risks

• The USPSTF recommends considering individual risk factors for thromboembolism and cardiovascular disease when prescribing estrogen therapy, such as estradiol valerate, and notes that contraindications include history of breast cancer, estrogen-dependent neoplasia, undiagnosed vaginal bleeding, and active thromboembolic disorders 2

Endometrial Protection

• The American College of Obstetricians and Gynecologists recommends that women with an intact uterus require progesterone therapy for endometrial protection when using estrogen therapy, such as estradiol valerate, as noted in guidelines from other societies 3